Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex312_6.htm |
| EX-31.1 - EX-31.1 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex311_7.htm |
| 10-Q - 10-Q - BIOMARIN PHARMACEUTICAL INC | bmrn-10q_20180930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
We, Jean-Jacques Bienaimé and Daniel Spiegelman, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc.
|
/s/ JEAN-JACQUES BIENAIMÉ |
|
Jean-Jacques Bienaimé |
|
Chief Executive Officer |
|
|
|
October 26, 2018
|
|
/s/ DANIEL SPIEGELMAN |
|
Daniel Spiegelman |
|
Executive Vice President and Chief Financial Officer |
|
|
|
October 26, 2018
|
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.